KRAS and non-small cell lung carcinoma: KRYSTAL-1 is a phase I/II trial of adagrasib monotherapy for previously treated advanced NSCLC with KRAS G12C mutation, and it demonstrated an ORR of 42.9% and mPFS of 6.5 months.